Sakditad Saowapa/X
Aug 6, 2025, 19:01
Sakditad Saowapa: FDA Approved Sunvozertinib for Metastatic NSCLC with EGFR Exon 20 Insertion
Sakditad Saowapa, Hematology-Oncology Fellow at University of Iowa, shared a post on X:
“FDA Accelerated Approval (2 Jul 2025)
Sunvozertinib (Zegfrovy) approved for metastatic NSCLC with EGFR exon 20 insertion after platinum chemo
WU-KONG1B trial (n=85)
ORR: 46% (95% CI: 35–57%)
DoR: 11.1 months (95% CI: 8.2–NE)
Companion Dx: Oncomine Dx Express Test
Warnings: ILD/pneumonitis, GI, skin, ocular, embryo-tox.”
More posts featuring FDA.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 22:57
Aug 6, 2025, 22:41
Aug 6, 2025, 22:14
Aug 6, 2025, 21:22
Aug 6, 2025, 21:07
Aug 6, 2025, 21:01
Aug 6, 2025, 20:49
Aug 6, 2025, 20:34